Nuvectis gains global rights outside select Asian markets for oncology and complement disease therapies, with Haisco eligible for milestone payments and royalties
34% of pharma firms have already deployed function-specific AI, with drug discovery, clinical trials, and medical writing emerging as key high-impact use cases
CDSCO-approved targeted therapy expands precision oncology options for patients with RET-driven lung, thyroid, and other advanced solid tumours
The company plans to use this funding to boost AI capabilities, expand vernacular content ecosystem, accelerate product development, and scale user acquisition across Tier 2 and Tier 3 markets
Intas Pharmaceuticals has appointed Girish Bhunje as Senior Vice President – API Operations
This makes the company among few in India to offer fully integrated, end-to-end ADC drug substance development and manufacturing, encompassing payload synthesis, linker development and manufacturing
In his 17-year career within Roche, Marco has held key global, regional, and affiliate leadership roles
As competition intensifies in the obesity treatment market, a next-generation therapy may be in development.
The findings come from the first and only decentralized real-world study examining how HD chorea affects patients and caregivers and how treatment impacts quality of life
The collaboration comes at a time when access to high-quality fertility treatment remains uneven, despite rapid market expansion
Subscribe To Our Newsletter & Stay Updated
